secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2026-06-02T20:01:14+00:00
Accession:  0001193125-26-253436
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences stockholders approve amended equity plan adding 1.85M new shares
--------------------------------------------------------------------------------

- Approved A&R 2021 Equity Incentive Plan with 1,850,000 newly requested shares; total reserve 5,190,000.
- Class III directors elected: Steven Kornfeld, Scott Brun, Paul A. Wagner (vote results provided).
- Advisory vote on named executive officer compensation for FY2025 passed (12.1M for, 3.8M against, 1.5M broker non-votes).
- KPMG ratified as independent auditor for FY2026 (17.7M for, 3K against, 40K abstentions).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/0001193125-26-253436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/d110060d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-253436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer